3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
214
Thoracic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
2646
Lymphoma, T-Cell, Cutaneous
479
Skin Neoplasms
408
Carcinoma, Non-Small-Cell Lung
377
Mycosis Fungoides
330
Neoplasms
319
Keratosis, Actinic
300
Sezary Syndrome
294
Breast Neoplasms
285
Neoplasm Metastasis
284
Carcinoma, Renal Cell
280
Lymphoma, Non-Hodgkin
276
Lymphoma
263
Carcinoma, Basal Cell
262
Lymphoma, Large B-Cell, Diffuse
261
Leukemia, Lymphocytic, Chronic, B-Cell
261
Lymphoma, Follicular
259
Hodgkin Disease
247
Lymphoma, Mantle-Cell
245
Lymphoma, B-Cell, Marginal Zone
245
Precursor Cell Lymphoblastic Leukemia-Lymphoma
243
Uveal Melanoma
234
Burkitt Lymphoma
233
Lymphoma, Large-Cell, Immunoblastic
223
Colorectal Neoplasms
196
Lymphoma, Large-Cell, Anaplastic
190
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
186
Ovarian Neoplasms
181
Squamous Cell Carcinoma of Head and Neck
180
Lung Neoplasms
179
Interventions
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Non-Muscle Invasive Bladder Neoplasms
×
Dermatologic
×
Clear all
NCT06448364
2024-11-06
LTbR
Pfizer
Phase 1
Terminated
4 enrolled